Peptide Comparison
CagrilintidevsTirzepatide
Long-acting amylin analog that supercharges satiety signals, delivering powerful appetite suppression and up to 10-15% weight loss with convenient once-weekly dosing.
The dual-action powerhouse that targets both GIP and GLP-1 receptors, delivering the most dramatic weight loss results ever seen in a medication—averaging over 20% body weight reduction while also crushing blood sugar levels in people with diabetes.
At a Glance
Quick
comparison
Dose Range
Cagrilintide
0.3–4.5 mg
Tirzepatide
2.5–15 mg
Frequency
Cagrilintide
Once weekly
Tirzepatide
Once weekly
Administration
Cagrilintide
Subcutaneous injection
Tirzepatide
Subcutaneous injection
Cycle Length
Cagrilintide
Ongoing/indefinite
Tirzepatide
Ongoing/indefinite
Onset Speed
Cagrilintide
Gradual (3-4 weeks)
Tirzepatide
Moderate (1-2 weeks)
Evidence Level
Cagrilintide
Strong human trials (Phase 3 or FDA approved)
Tirzepatide
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Appetite Control
Weight Loss
GLP-1 Synergy
Blood Sugar Control
Technical Data
Compound
specifications
Cagrilintide
Molecular Formula
C194H312N54O59S2
Molecular Weight
4409 g/mol
Half-Life
159-195 hours (~7-8 days)
Bioavailability
~100% (subcutaneous)
CAS Number
1415456-99-3
Tirzepatide
Molecular Formula
C225H348N48O68
Molecular Weight
4813.45 g/mol
Half-Life
Approximately 5 days (120 hours)
Bioavailability
~80% (subcutaneous)
CAS Number
2023788-19-2
Protocols
Dosing
tiers
Cagrilintide
Tirzepatide
Applications
Best
suited for
Cagrilintide
Weight loss and appetite control
Cagrilintide excels at reducing hunger by mimicking amylin, a hormone your pancreas naturally releases after meals. Phase 2 trials showed people losing up to 10.8% of body weight with cagrilintide alone - and that's without combining it with other medications.
Boosting GLP-1 medication results
When you hit a plateau with semaglutide or want even better results, cagrilintide adds a second satiety pathway. The CagriSema combination achieved over 20% weight loss in clinical trials - significantly more than either drug alone.
People who want once-weekly convenience
Unlike older amylin medications that required three daily injections, cagrilintide's extended half-life of about a week means you only inject once weekly. Set a reminder on your phone and you're done.
Those seeking natural-feeling appetite reduction
Cagrilintide works by enhancing your body's own fullness signals rather than forcing you to eat less. Many users report feeling genuinely satisfied with smaller meals rather than fighting willpower battles.
Metabolic health improvement
Beyond weight loss, cagrilintide helps with blood sugar control and metabolic markers. It slows stomach emptying and reduces post-meal glucose spikes, making it valuable for people with or at risk for type 2 diabetes.
Tirzepatide
People Who Want Maximum Weight Loss Results
If you're serious about losing significant weight, tirzepatide delivers results that were previously only achievable through bariatric surgery. Clinical trials showed average weight loss exceeding 20% of body weight—that's 50+ pounds for someone starting at 250 pounds. No other medication comes close.
Those Who Haven't Succeeded with Semaglutide
Thanks to its dual GIP/GLP-1 mechanism, tirzepatide often works better for people who had limited results with GLP-1-only drugs like semaglutide. The added GIP activation provides extra metabolic benefits that can break through plateaus and deliver superior weight loss.
People with Type 2 Diabetes Needing Aggressive Control
Head-to-head trials proved tirzepatide beats semaglutide for blood sugar control. The average HbA1c reduction of over 2 percentage points means many people can dramatically reduce or eliminate other diabetes medications. It's a genuine game-changer for metabolic health.
Individuals Looking to Transform Their Relationship with Food
Tirzepatide doesn't just reduce hunger—it fundamentally changes how food appeals to you. Users describe feeling free from constant food thoughts, finding it easy to stop eating when satisfied, and losing interest in formerly irresistible treats. It's not willpower—it's biochemistry working for you.
Safety Profile
Side
effects
Cagrilintide
Common
- Nausea
- Constipation
- Diarrhea
- Injection site reactions
Uncommon
- Vomiting
- Headache
Serious
- Severe allergic reactions
Tirzepatide
Common
- Nausea
- Diarrhea
- Decreased Appetite
- Vomiting
Uncommon
- Gallbladder Problems
- Hair Thinning (Telogen Effluvium)
Serious
- Pancreatitis
- Thyroid Tumors (Theoretical Risk)
Research Status
Safety
& evidence
Cagrilintide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
Not FDA approved
Safety Overview
Cagrilintide has been studied in multiple Phase 2 and Phase 3 trials involving thousands of participants. The safety profile is generally favorable, with most side effects being GI-related (nausea, constipation, diarrhea) that improve with time and gradual dose escalation. Serious adverse events are rare, and the drug was well-tolerated even at the highest studied doses.
Contraindications
- xPregnancy or breastfeeding
- xActive eating disorders
- xPersonal history of medullary thyroid carcinoma
- xSevere gastroparesis
Tirzepatide
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Tirzepatide has been extensively studied in the SURPASS (diabetes) and SURMOUNT (obesity) trial programs, involving thousands of participants over multiple years. The FDA approved it after thorough safety review. While GI side effects are common (especially during dose increases), they're typically mild to moderate and improve over time. Serious adverse events are rare. The SURPASS-CVOT trial is ongoing to evaluate long-term cardiovascular outcomes.
Contraindications
- xPersonal or family history of medullary thyroid carcinoma (MTC)
- xMultiple Endocrine Neoplasia syndrome type 2 (MEN2)
- xHistory of serious allergic reaction to tirzepatide or any GLP-1/GIP medication
- xCurrent or recent pancreatitis
- xPregnancy or planning to become pregnant
Decision Guide
Which is
right for you?
Choose Cagrilintide if...
- Weight loss
- Appetite control
- Metabolic health
- GLP-1 augmentation
Choose Tirzepatide if...
- Maximum weight loss results
- Long-term obesity management
- Type 2 diabetes control
- Metabolic health improvement